Stopping rules for phase II studies.

This paper, the second in a series of three papers concerned with the statistical aspects of interim analyses in clinical trials, is concerned with stopping rules in phase II clinical trials. Phase II trials are generally small-scale studies, and may include one or more experimental treatments with or without a control. A common feature is that the results primarily determine the course of further clinical evaluation of a treatment rather than providing definitive evidence of treatment efficacy. This means that there is more flexibility available in the design and analysis of such studies than in phase III trials. This has led to a range of different approaches being taken to the statistical design of stopping rules for such trials. This paper briefly describes and compares the different approaches. In most cases the stopping rules can be described and implemented easily without knowledge of the detailed statistical and computational methods used to obtain the rules.

[1]  Peter F. Thall,et al.  Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. , 1998 .

[2]  A Whitehead,et al.  Interim analyses and sequential designs in phase III studies. , 2001, British journal of clinical pharmacology.

[3]  J Whitehead,et al.  Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes , 1999, Biometrics.

[4]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[5]  N. Stallard.  Approximately optimal designs for phase II clinical studies. , 1998, Journal of biopharmaceutical statistics.

[6]  T. Chen,et al.  Optimal three-stage designs for phase II cancer clinical trials. , 1997, Statistics in medicine.

[7]  J Whitehead,et al.  Designing phase II studies in the context of a programme of clinical research. , 1985, Biometrics.

[8]  Donald A. Berry,et al.  Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs , 1994 .

[9]  P F Thall,et al.  A two-stage design for choosing among several experimental treatments and a control in clinical trials. , 1989, Biometrics.

[10]  M R Conaway,et al.  Bivariate sequential designs for phase II trials. , 1995, Biometrics.

[11]  E. Gehan,et al.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.

[12]  T M Therneau,et al.  Designs for group sequential phase II clinical trials. , 1987, Biometrics.

[13]  P F Thall,et al.  Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.

[14]  S Chen,et al.  An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives. , 1994, Controlled clinical trials.

[15]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[16]  D. Heitjan,et al.  Bayesian interim analysis of phase II cancer clinical trials. , 1997, Statistics in medicine.

[17]  D A Berry,et al.  One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. , 1988, Biometrics.

[18]  N Stallard,et al.  Sample size determination for phase II clinical trials based on Bayesian decision theory. , 1998, Biometrics.

[19]  N. Cressie,et al.  A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials. , 1994, Biometrics.

[20]  D. Schoenfeld,et al.  Statistical considerations for pilot studies. , 1980, International journal of radiation oncology, biology, physics.

[21]  J Whitehead,et al.  Sample sizes for phase II and phase III clinical trials: an integrated approach. , 1986, Statistics in medicine.

[22]  P F Thall,et al.  A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. , 1993, Statistics in medicine.